Evolution of AI and big data in the biopharmaceutical industry: perspectives of industry specialists from Europe

Emma Frederick
Rudolf-Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, Faculty of Medicine, Leipzig University, Leipzig, Germany
Ben Alexander
Institute of Bioprocess and Biosystems Engineering, Hamburg University of Technology, Hamburg, Germany

DOI:https://doi.org/10.5912/jcb2138

Abstract:

This paper examines the complex relationship between the evolution of artificial intelligence (AI) and big data and the growth of the biopharmaceutical industry in Europe. It analyzes the perspectives of industry specialists to understand how AI and big data are transforming research, development, and strategy. The paper hypothesizes that adopting AI and big data indirectly promotes industry expansion, and that DevOps adoption challenges mediate while market optimization moderates this relationship. A quantitative methodology was used involving a survey of European biopharmaceutical experts. The analysis supported the hypothesis that using big data and AI adoption indirectly boosts industry growth. However, DevOps challenges were found not to significantly mediate this relationship. As hypothesized, market optimization was found to positively moderate the impact of AI adoption on growth. The paper makes key theoretical contributions by elucidating the role of AI, big data and market factors in propelling industry advancement. It also offers tangible practical insights to help firms leverage these technologies to enhance competitiveness.